Skip to content
MarketScale
‹ Back to IndustriesSciences

Composites Lighten RVs, Offer More Durability, Too

RVs and caravans far outweigh standard automobiles. However, that weight can also create lots of challenges in moving down the highway. Lightening that load in creative ways ensures a smoother ride without compromising the integrity of the vehicle. One of the best solutions to reducing weight is through the use of composites and MVP equipment….

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Sciences · Promoted Content
Share
Composites Lighten RVs, Offer More Durability, Too

Key takeaways

01

RVs and caravans far outweigh standard automobiles.

02

However, that weight can also create lots of challenges in moving down the highway.

03

Lightening that load in creative ways ensures a smoother ride without compromising the integrity of the vehicle.

RVs and caravans far outweigh standard automobiles. However, that weight can also create lots of challenges in moving down the highway. Lightening that load in creative ways ensures a smoother ride without compromising the integrity of the vehicle. One of the best solutions to reducing weight is through the use of composites and MVP equipment. Some of those reasons are highlighted below:

Industry Sees Push to Get Light

Reducing the weight of RVs is a trending topic in the industry. In a recreational vehicle, it is estimated that for every pound of mass removed, another pound of consumer comfort can be added without affecting towing capacity. In addition, an overall lighter RV translates to a less expensive drive train or tow vehicle, meaning less fuel consumption and reduced cost of ownership.[1]

Time to Shift from Wood

Commonly used in RV manufacturing, wood is rapidly being perceived as an unsuitable material due to its weight and susceptibility to water intrusion and rot. In addition, post-purchase maintenance of wood products can be extremely cost prohibitive. According to a Composites World article, it could cost up to $10,000 to replace a single RV panel of wood.[2]Now that there are better alternatives from a material standpoint offering longer lifespans, those are the materials that should be used. And for those wood loving RV owners, these alternatives can still include wood finishes.

Time to Shift to Composites

A composite material, by nature, is flexible, so it can be easily formed to the shapes and sizes necessary in RV manufacturing. These efficient materials are not only changing how these vehicles are made, but the end user experience as well. By offering innovation in production, manufacturers are now producing longer lasting, higher quality products to the customer’s benefit. Lighter composites are attractive, making the replacement of heavier, bulkier manufacturing materials aesthetically beneficial. And composites are durable—they don’t rust when used in flooring, and have better resistance to leakage when fitting skylights in roofing.

New Composite Hits the Market

The composite market is ripe for innovation as the need for slimmed down campers and caravans continues. While better fuel mileage is an added bonus, the focus on reduced weight is really about a better overall performance of the vehicle. A ceramic-matrix composite (CMC) is a new material with attributes that include low density, high hardness, and high compressive strength, and remains stable in thermal or chemical situations. In addition, CMC has ceramic fiber reinforcement for extreme low fracture toughness to mitigate crack growth. And with the capability to be manufactured up to 35% lighter with a price increase of just about 10%, it’s also possible to design the strength and density of CMC based on specific application, with the potential to revolutionize production too.

Composite Tools for the RV World

As a partner to RV manufacturers, Magnum Venus Products (MVP) delivers quality composite equipment, including pumping systems, spray guns, and more. Our goal is to help recreational vehicles look and perform optimally. Using composite materials in production ultimately helps to keep RVs and their owners on the road longer. Learn more about how our tools work by reading some of our case studies.

Read more at mvpind.com

[1] https://www.compositesworld.com/articles/mass-reduction-for-mass-appeal-frps-and-cmcs-in-rvs

[2] https://www.compositesworld.com/articles/mass-reduction-for-mass-appeal-frps-and-cmcs-in-rvs

About the author

S
Sciences

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

The pharmaceutical industry is facing a significant challenge as over $300 billion in branded pharmaceutical revenue is set to lose patent protection by 2030. This revenue gap is driving the largest merger and acquisition cycle seen in a decade, with companies seeking external growth through acquisitions. This shift is impacting the entire life sciences supply chain, prompting strategic changes across the industry.

  • 01Over $300 billion in pharmaceutical revenue is at risk due to patent expirations by 2030.
  • 02Big Pharma is engaging in an aggressive cycle of mergers and acquisitions.
  • 03The acquisitions are reshaping the life sciences supply chain.

Jun 29, 2026

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences has initiated a Phase I clinical study of an oral solid dose formulation designed using AI, cleared by the UK's MHRA and conducted at the company's UK facility. The trial—built on machine learning algorithms from partner Intrepid Labs and Quotient's Translational Pharmaceutics platform—aims to validate AI as a direct contributor to formulation design rather than just an upstream analytical tool. Benchling characterizes the broader moment as biotech entering a "builder phase," in which leading organizations embed AI capability at the bench level rather than running isolated pilots.

  • 01Quotient Sciences has dosed healthy volunteers in a Phase I study it describes as the first clinical evaluation of an AI-designed oral formulation, following approval from the UK's MHRA.
  • 02The formulation was developed using advanced machine learning algorithms from Intrepid Labs, integrated with Quotient Sciences' Translational Pharmaceutics platform.
  • 03Benchling identifies a sector-wide shift toward embedding AI capability directly at the bench, moving beyond isolated pilots to structural adoption across biotech R&D.

Jun 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

S
Sciences

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512